ProfileGDS5678 / 1426368_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 89% 90% 87% 86% 90% 89% 90% 91% 88% 86% 88% 88% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9429489
GSM967853U87-EV human glioblastoma xenograft - Control 27.077489
GSM967854U87-EV human glioblastoma xenograft - Control 37.3287190
GSM967855U87-EV human glioblastoma xenograft - Control 46.939887
GSM967856U87-EV human glioblastoma xenograft - Control 56.5899986
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9273990
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.8679989
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.1017890
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.359191
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9243188
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4562886
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8856788
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8209688
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.0187789